Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Sales (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Return on Sales for 4 consecutive years, with 0.15% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 14968.0% to 0.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.29% through Dec 2025, up 79.0% year-over-year, with the annual reading at 0.29% for FY2025, 46.0% up from the prior year.
  • Return on Sales hit 0.15% in Q4 2025 for Axsome Therapeutics, up from 0.28% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.12% in Q1 2023 to a low of 149.82% in Q4 2024.
  • Historically, Return on Sales has averaged 11.16% across 4 years, with a median of 0.91% in 2024.
  • Biggest five-year swings in Return on Sales: tumbled -14844bps in 2024 and later soared 14968bps in 2025.
  • Year by year, Return on Sales stood at 2.51% in 2022, then surged by 45bps to 1.38% in 2023, then plummeted by -10763bps to 149.82% in 2024, then skyrocketed by 100bps to 0.15% in 2025.
  • Business Quant data shows Return on Sales for AXSM at 0.15% in Q4 2025, 0.28% in Q3 2025, and 0.32% in Q2 2025.